Research programme: monoclonal antibodies - AstraZeneca/Integral Molecular
Latest Information Update: 29 Dec 2021
At a glance
- Originator Integral Molecular
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer